Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Oral Microbiome and Serum Metabolome Alterations in Epilepsy and after Seizure Controloral Microbiome and Serum Metabolome Alterations in Epilepsy and after Seizure Control
54 Pages Posted: 16 Aug 2022
More...Abstract
Background: The existing diagnostic methods of epilepsy such as history collection and EEG has great limitations in practice, so more reliable and less difficult diagnostic methods are needed.
Methods: 16S rRNA sequencing was performed on 480 tongue swabs (157 EPs, 22 EPRs, and 301healthy controls (HCs)). Untargeted metabolomics analysis was performed on 432 serum samples (131 EPs, 19 EPRs, and 282 HCs).
Findings: At the genus level, Streptococcus and Leptotrichia increased in EP, though Neisseria and Schaalia decreased. In serum metabolomics, d-glutamine and d-glutamate metabolism and cutin, suberine and wax biosynthesis were altered in EP and EPR. Compared with EP, sphingolipid metabolism was enhanced in EPR. The diagnostic efficacy of oral microbial markers in training cohort and validation cohort was 98.85% and 97.23%, respectively. Importantly, the biomarker set achieved a diagnostic efficacy of 92.44% in additional independent validation sets. The diagnostic ability of the 4-metabolite model was 99.4% in the training cohort and 100% in the validation cohort.
Interpretation: In conclusion, this study describes the characterization of oral microbiome and serum metabolites in EP and EPR and demonstrates the potential of specific microbiome and metabolites as non-invasive diagnostic tools for epilepsy.
Funding Information: This study was sponsored by grants from National Key Research and Development Program of China (2018YFC2000501), National Natural Science Foundation of China (U2004121, 82070643, and U1904164), and Research Project of Jinan Microecological Biomedicine Shandong Laboratory (JNL-2022001A).
Declaration of Interests: All authors declare that they have no competing interests.
Ethics Approval Statement: This study was approved by the Institutional Review Board from the First Affiliated Hospital of Zhengzhou University (2019-039). The study was performed in accordance with the Helsinki Declaration and Rules of Good Clinical Practice. All participants signed written informed consent after the study protocol was fully explained.
Keywords: Keywords: Epilepsy, Seizure control, Oral microbiome, Serum metabolome, Diagnostic model
Suggested Citation: Suggested Citation